Novo nordisk On Saturday, its diabetes pellet Raybelus showed cardiovascular benefits in late phase testing, paving the way for people suffering from diabetes and heart disease to become a new treatment option.
The bullet reduced the risk of cardiovascular death, heart attack and stroke by 14%, which in diabetes patients fell to 14% after a average of four years after a placebo, and established heart disease with or without chronic kidney disease. The Danish drug manufacturer presented results on the Raybelus, already approved for type 2 diabetes in the annual scientific session of the American College of Cardiology in Chicago.
The company’s global chief medical officer Stephen Gaf said in an interview, Novo Nordisk has already stated in the US and the European Union that to expand the approval of the pill to reduce the risk of serious cardiovascular complications, the company’s global Chief Medical Officer said in an interview.
The blockbuster diabetes injection of Rybelsus Novo Nordisk is a bar-in-the-world oral formulation, which is taken once a week. Both remedies, as well as the company’s weekly weight loss injection vegovies include semglutide active ingredients.
In March 2024, Vagovi won the US approval to reduce the risk of major cardiovascular events in adults with heart disease and which are thick or overweight. But the pill data presented on Saturday suggests that patients who are hesitant to take injections, such as people who are afraid of needles, may soon use treatment in a more convenient way.
“We know that not everyone wants an injection, whether it is painful or not, they want an oral medicine option,” Guff told CNBC. “We provide that option that you can have one or the other, it depends on that patients and healthcare professional ideas are correct in that joint discussion.”
The data comes as a slate of other drug manufacturers, including Ellie Lily, Work to develop oral GLP-1s for diabetes, weight loss and other conditions such as sleep apnea.
Step three tests only tested more than 9,600 patients and received rybelus or placebo over 50 years of age, both at the top of their standard treatment, for an average of only four years. About half of all patients received drugs called SGLT2 inhibitors, which are mainly used to reduce blood sugar in adults with type 2 diabetes at some point during testing.
By the end of the test, 12% of the people taking Rybelsus and 13.8% of the 13.8% location of the experienced heart-related death, heart attack or stroke. It represents 14% of overall low risk among those who took Rybelsus.
Researchers stated that low risk is in line with the heart benefits seen in the eight previous tests, including the injectable GLP -1S, including semaglutide and other popular drugs, according to a release from the American College of Cardiology. GLP-1s have mimicked some intestinal hormones to reduce appetite and regulate blood sugar, but also have other effects such as reducing inflammation.
Ribbelus helped reduce the risk of non-fatal heart attack to 26% compared to Placebo, which was the “primary driver” of the overall decrease of risk for cardiovascular complications in the test, stated in the release. The tablet reduced the risk of non-fatal stroke to 12% and cardiovascular death by 7% compared to Placebo.
Release said that there was no significant difference between Rybelus and Placebo groups in the results related to kidney work. But the test was “clearly”, which was designed to examine the heart rather than the benefit of the bullet kidney, Gaf said.
Is ozmpic Already approved To treat chronic kidney disease in patients with diabetes.
The most common side effects mentioned in the study were gastrointestinal issues, such as nausea, diarrhea, and constipation, which rarely motivated patients to stop the ribelus according to the release, according to the release. Those symptoms correspond to the side effects of injection semglutide.
Similar results were seen in all subgroups of patients – age, gender, and the beginning of testing among people with various health conditions, stated in the release.
Unlike its injectable counterparts, the raybelus should be taken on an empty stomach at least 30 minutes before breakfast with a small amount of water. Despite those requirements, the study “provides assurance that patients were directed as a drug and were able to take medicines as cardiac health benefits,” Dr. Dr. Dr. Dr. of Medicine at UT Southwestern Medical Center. Darren McGire said.
